Oral efficacy of WIN 51711 in mice infected with human poliovirus.
WIN 51711, a new broad-spectrum anti-picornavirus agent, prevented the development of paralysis and subsequent death in mice infected intracerebrally with a lethal dose of human poliovirus type 2 (MEF strain). The prophylactic efficacy of intragastrically administered WIN 51711 was dose dependent over the 3.9- to 62.5-mg/kg (twice daily) dose range, with a minimal significantly effective dose of less than 15.6 mg/kg per dose (twice daily) (P less than 0.008). An oral four times a day dosage regimen initiated 48 h postinfection with WIN 51711 doses as low as 12.5 mg/kg was effective in significantly reducing poliovirus-induced paralysis and death compared with a placebo. Viral titers in the brains and spines of mice infected intracerebrally with 200 50% lethal doses of poliovirus were reduced by 3 to 5 log10 PFU/g in the WIN 51711-medicated group compared with placebo-medicated animals. The potent in vitro and in vivo anti-picornavirus activity of WIN 51711 makes it a potentially useful drug for the treatment of enterovirus infections in humans.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001921:Brain / Q000382:microbiology; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D051379:Mice; D008813:Mice, Inbred ICR; D010080:Oxazoles / Q000627:therapeutic use*; D011051:Poliomyelitis / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D013116:Spinal Cord / Q000382:microbiology; D013997:Time Factors
D000998:Antiviral Agents; D007555:Isoxazoles; D010080:Oxazoles; C045978:disoxaril